Archive for: Drug Pricing

  • ORIGINAL ANALYSIS

  • PDF DOWNLOAD

  • EXTERNAL LINK

  • POST

Insight: original analysis

McDermottPlus Check-Up: December 06, 2019

Congress is back in town with just two weeks to address government funding and many healthcare issues. More proposals are emerging on drug pricing and surprise billing, and the House Judiciary Committee took up impeachment.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Healthcare Preview: October 28, 2019

A House Vote on Prescription Drug Pricing Reforms Slips as We Approach a One Week Recess in the House.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: October 25, 2019

The House Ways and Means Committee completed its markup of H.R. 3, but floor consideration was pushed until mid-November. Seema Verma appeared before the House Energy and Commerce Oversight and Investigations Subcommittee.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Healthcare Preview: October 21, 2019

Administrator Verma is testifying, and the debate on prescription drug pricing reforms continues.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Healthcare Preview: October 14, 2019

Congress is back for a six week stretch. And the Healthcare Preview podcast is now available on Sound Cloud.

ORIGINAL ANALYSIS

Insight: original analysis

Overlapping Provisions in Major Healthcare Bills 2019

Lawmakers came with big ambitions for 2019, but we are headed into 2020 with two major health policies left on life support and many healthcare programs nearing expiration.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Health Care Preview: September 30, 2019

Congress is out on a two recess, but the effects of the impeachment inquiry will have long lasting impacts.  

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: September 20, 2019

This Week’s Dose: Speaker Pelosi released her long-awaited drug pricing bill, and the House Energy and Commerce Committee questioned drug companies’ financial motivations during a hearing this week.

ORIGINAL ANALYSIS

Insight: original analysis

The Overlap of Drug Pricing Proposals

On September 19, 2019, the Speaker of the US House of Representatives released a proposal to contain federal and individual spending on prescription drugs, joining Administration and Senate efforts to address prescription drug pricing. This article contemplates the likelihood of a drug pricing package and how it could come together.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: July 26, 2019

This Week’s Dose: The Senate Finance Committee finally released its drug pricing package and moved quickly to a markup. The bill passed out of committee, but work will continue before the full Senate votes. We’ll be watching closely as things develop.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Health Care Preview: July 22, 2019

This is the last scheduled week the House is in session and the second to last week the Senate is in session before the August recess.  What will get done?

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: July 12, 2019

This Week’s Dose: Congress is back for the final legislative session before the August recess, and it’s all about what can get done ahead of the break. House and Senate committees have already advanced a cost containment legislation that includes surprise billing and prescription drug cost provisions, among many other things. We still await any…

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: June 28, 2019

This Week’s Dose: Lots of movement in Congress ahead of the Fourth of July recess with the House and Senate both advancing a number of health care bills. President Trump also signed an executive order this week, continuing the Administration’s focus on health care transparency.

POST

Insight: original analysis

McDermottPlus Check-Up: June 21, 2019

This Week’s Dose: Three weeks down, one week to go in this work period. The Senate Health, Education, Labor and Pensions (HELP) Committee is moving forward with its cost containment legislation, and the House passed the first batch of health care extenders.

ORIGINAL ANALYSIS

Insight: original analysis

Key Changes in HELP’s Updated Lower Health Care Costs Act

On June 19, 2019, the US Senate Committee on Health, Education, Labor & Pensions (HELP) released its updated Lower Health Care Costs Act (S. 1895). This new version includes several noteworthy changes, outlined below.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: June 7, 2019

This Week’s Dose: Congress is back, and this week marked the start of another busy legislative session. Work continues on drug pricing, surprise billing and cost containment, and negotiations have begun on an extenders package as well.

ORIGINAL ANALYSIS

Insight: original analysis

CMS Releases Final Rule Aimed at Lowering Drug Prices and Reducing Out-of-Pocket Spending

Since mid-2018, the Centers for Medicare and Medicaid Services has been implementing sections of the American Patients First Blueprint, President Trump’s plan to lower drug prices and reduce patient out-of-pocket spending.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: May 10, 2019

This Week’s Dose: Another busy week for prescription drug pricing. Two more hearings took place on the subject, and a handful of bills passed out of the House. Now we watch the Senate to see how it packages and advances prescription drug bills that have moved through the House.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: May 3, 2019

This Week’s Dose: Lots of activity surrounding single-payer this week with a hearing, the introduction of two Medicare expansion bills and a report from the Congressional Budget Office (CBO). Hearings and markups of drug pricing bills continue as well. This legislative session is off to a busy start.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: April 12, 2019

This Week’s Dose: Drug pricing continues to be the focus in Congress with multiple hearings and markups on the subject. So far, lowering drug prices remains a rare area of consensus among lawmakers.

ORIGINAL ANALYSIS

Insight: original analysis

Analyzing the President’s FY 2020 Budget: Key HHS Proposals

On March 11, 2019, the White House released its FY 2020 budget proposal. In the area of health care, the president has requested $87.1 billion in discretionary budget authority for HHS, which represents a 12 percent decrease from the 2019 estimated level. Read on for key HHS proposal highlights.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: March 8, 2019

This Week’s Diagnosis: Hearings, hearings and more hearings. FDA Commissioner Scott Gottlieb is stepping down. Budget talks heat up.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: February 22, 2019

This Week’s Diagnosis: It’s all quiet on the Hill. Members return Monday after the first full week of district work time in the 116th Congress.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: February 15, 2019

This Week’s Diagnosis: Congress passed a $328 billion spending package to avert another government shutdown.  President Trump is expected to sign it.  Congressional hearings continue to focus on coverage and drug pricing.  

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: February 8, 2019

This Week’s Dose: The State of the Union briefly highlighted a few Administration health initiatives. The House continues its focus on the Affordable Care Act (ACA). The Senate is pressuring CEOs from the largest drug manufacturers to testify.  

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: February 1, 2019

This Week’s Diagnosis: Government reopens…for at least three weeks. Congress is full steam ahead, kicking off the 116th with health care hearings on drug pricing and pre-existing conditions. The US Department of Health and Human Services focuses on 2019 priorities.

ORIGINAL ANALYSIS

Insight: original analysis

McDermott Plus Check-up: January 25, 2019

This Week’s Diagnosis: Hearings are beginning and priorities are emerging. The shutdown drags on. And updates are trickling out of the Administration.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: January 11, 2019

This Week’s Diagnosis: Welcome back – sort of. The partial federal government shutdown drags on. We are on day 21 with no end in sight, which has shifted the focus of the new Congress away from overarching health priorities and toward continued efforts to reopen the government.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: December 7, 2018

This Week’s Diagnosis: Memorial services for President George H.W. Bush were held this week in Washington, DC and Texas. No agreement has been reached on border wall funding, which means Members may be here through at least December 21.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: November 30, 2018

This Week’s Diagnoses: Welcome back! Members are back in town for a sprint to the finish. Controversy over the House Democratic leadership elections fizzled, with the same faces in the top three positions.

ORIGINAL ANALYSIS

Insight: original analysis

Election Results Bring Change in Health Priorities

Democrats will take control of the House of Representatives in January 2019. Republicans will retain control of the Senate, widening their margin slightly. Split control of Congress will have important consequences for healthcare policy.  This article takes a closer look at how the election is likely to impact the health policy agenda.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: October 26, 2018

This Week’s Diagnosis: The Administration remains active with the issuance of several new guidance documents, the drug pricing announcement and the President (finally) signing the bipartisan opioid legislation (HR 6).

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: October 19, 2018

This Week’s Diagnoses: All eyes are on the midterm election, now less than three weeks away.  The House and Senate are out; the Administration continues to release health-related regulations and announcements.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: September 28, 2018

This Week’s Diagnosis: Consideration of the Kavanaugh nomination dominated airtime in the Senate this week, but the House stayed on-task, pushing through a number of health-related bills.

ORIGINAL ANALYSIS

Insight: original analysis

Oklahoma Is the Place to Be . . . Especially for Value-Based Contracting

This article—the latest in a McDermott+Consulting series investigating the president’s drug pricing plans—takes a closer look at Oklahoma’s recently approved State Plan Amendment that allows Oklahoma to negotiate value-based contracts with drug makers for individuals covered by the state’s Medicaid plan.

ORIGINAL ANALYSIS

Insight: original analysis

White House Builds Momentum for Drug Price Controls

On May 11, 2018, President Trump released the American Patients First Blueprint, a plan to lower drug prices and reduce beneficiary out-of-pocket spending on drugs in the Medicare program.

ORIGINAL ANALYSIS

Insight: original analysis

White House Swings for Fences with FY 2019 Drug Pricing Proposals

Since the run-up to the 2016 presidential election, Donald Trump has stated his interest in controlling and lowering the high cost of prescription drugs. Until recently his administration had released limited details on possible ways to do so.

ORIGINAL ANALYSIS

Load more
beakernav X1E2BFA62-BFCE-43C1-B777-27E3E5216018medical bagoriginal analysis +external linkpdf downloadstethoscope